Additional file 1 of Lower myostatin and higher MUC1 levels are associated with better response to mepolizumab and omalizumab in asthma: a protein–protein interaction analyses
Creators: name: Akenroye, Ayobami
name: Nopsopon, Tanawin
name: Cho, Laura
name: Moll, Matthew
name: Weiss, Scott T.
Publisher: name: figshare
Year: 2024
Subjects: subject: Biochemistry
subject: Medicine
subject: Genetics
subject: FOS: Biological sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Cancer
subject: Infectious Diseases
subject: FOS: Health sciences

description: Additional file 1: Figure S1. Heat map of proteins associated with exacerbations after initiation of mepolizumab. Patients are presented on the x-axis by risk difference defined as the difference between the individual’s exacerbation rate in the one year after starting mepolizumab and the exacerbation rate in the year prior to mepolizumab initiation. Proteins are presented on the y-axis using hierarchical clustering with Euclidean distance and the Ward clustering based on log2-transformed and row-scaled protein expression. Heat map colors ranged from lower (purple) to higher (yellow) protein expression. Figure S2. Functional annotation of corresponding genes of proteins associated with the change in exacerbations on mepolizumab. The gene set enrichment analysis (GSEA) was conducted using the biological processes (BP) domain of Gene Ontology (GO). GO term with false discovery rate (FDR) &lt; 0.20 were considered statistically significant. GSEA enrichment plot of top 4 significant gene set. The curves indicated the running cumulative enrichment score. Red (blue) line represented biological process associated with higher (lower) exacerbation. The barcode plot presented the position of genes related to the gene set. Figure S3. Represented a gene set (a GO term). The smaller node represented each gene with color indicating ranked metric ranged from red (higher exacerbations) to green (lower exacerbations). Edge indicated the membership of gene set. The gene set enrichment analysis (GSEA) was conducted using the biological processes (BP) domain of Gene Ontology (GO). GO term with false discovery rate (FDR) &lt; 0.20 were considered statistically significant. Figure S4. Heat map of top 80 proteins associated with exacerbations after initiation of omalizumab. Patients are presented on the x-axis by risk difference defined as the difference between the individual’s exacerbation rate in the one year after starting omalizumab and the exacerbation rate in the year prior to omalizumab initiation. Proteins are presented on the y-axis using hierarchical clustering with Euclidean distance and the Ward clustering based on log2-transformed and row-scaled protein expression. Heat map colors ranged from lower (purple) to higher (yellow) protein expression. Figure S5. Functional annotation of corresponding genes of proteins associated with the change in exacerbations on omalizumab. The gene set enrichment analysis (GSEA) was conducted using the biological processes (BP) domain of Gene Ontology (GO). GO term with false discovery rate (FDR) &lt; 0.20 were considered statistically significant. GSEA enrichment plot of top 4 significant gene sets. The curves indicated the running cumulative enrichment score. Red line represented biological process associated with higher exacerbation. The barcode plot presented the position of genes related to the gene set. Figure S6. Gene-Concept network plot for omalizumab group. The cnetplot presented the network of interacting genes among top 5 significant gene sets. The yellow node represented a gene set (a GO term). The smaller node represented each gene with color indicating ranked metric ranged from red (higher exacerbation) to white (lower exacerbation). Edge indicated the membership of gene set. The gene set enrichment analysis (GSEA) was conducted using the biological processes (BP) domain of Gene Ontology (GO). GO term with false discovery rate (FDR) &lt; 0.20 were considered statistically significant. Table S1. Proteins associated with change in exacerbations in the mepolizumab group. Table S2. Enriched gene sets in the mepolizumab group using Gene ontology (GO). Table S3. Markov Algorithm-based Clusters associated with mepolizumab response. Table S4. Top KEGG pathways enriched in association with mepolizumab response. Table S5. Proteins associated with change in exacerbations in the omalizumab group. Table S6. Top 20 enriched gene sets in the omalizumab group using Gene Ontology (GO). Table S7. Markov Algorithm-based Clusters associated with omalizumab response. Table S8. Top 22 KEGG pathways enriched in association with omalizumab response.